(Q51969151)

19 April 2018

title

Olanzapine versus risperidone. A prospective comparison of clinical and economic outcomes in schizophrenia. (English)

1 reference

19 April 2018

0 references

E T Edgell

1

1 reference

19 April 2018

S W Andersen

2

1 reference

19 April 2018

B M Johnstone

3

1 reference

19 April 2018

B Dulisse

4

1 reference

19 April 2018

D Revicki

5

1 reference

19 April 2018

A Breier

6

1 reference

19 April 2018

publication date

1 December 2000

1 reference

19 April 2018

published in

PharmacoEconomics

1 reference

19 April 2018

volume

18

1 reference

19 April 2018

issue

6

1 reference

19 April 2018

page(s)

567-579

1 reference

19 April 2018

https://scigraph.springernature.com/pub.10.2165/00019053-200018060-00004

exact match

0 references

cites work

Pharmacoeconomics of antipsychotic drug therapy

1 reference

12 December 2020

Comments on article by Tran and associates, "Double-blind comparison of olanzapine versus risperidone in treatment of schizophrenia and other psychotic disorders"

1 reference

12 December 2020

Drug utilization patterns and outcomes associated with in-hospital treatment with risperidone or olanzapine

1 reference

12 December 2020

Clozapine for the treatment-resistant schizophrenic. A double-blind comparison with chlorpromazine

1 reference

12 December 2020

Savings in hospital bed-days related to treatment with clozapine.

1 reference

12 December 2020

Cost effectiveness of clozapine in neuroleptic-resistant schizophrenia.

1 reference

12 December 2020

Clinical and economic outcomes of olanzapine compared with haloperidol for schizophrenia. Results from a randomised clinical trial

1 reference

12 December 2020

Conventional antipsychotic medications for schizophrenia

1 reference

12 December 2020

Cost-effectiveness of clozapine for treatment-resistant schizophrenic patients.

1 reference

12 December 2020

A rating scale for drug-induced akathisia

1 reference

12 December 2020

Comments on article by Tran and colleagues, "Double-blind comparison of olanzapine versus risperidone in treatment of schizophrenia and other psychotic disorders"

1 reference

12 December 2020

The economic value of atypical antipsychotics: A comparison of risperidone and olanzapine revisited

1 reference

12 December 2020

The distinction between cost and charges

1 reference

12 December 2020

Economic analysis and clinical trials

1 reference

12 December 2020

Recent advances in the pharmacotherapy of schizophrenia

1 reference

12 December 2020

Impact of risperidone on the use of mental health care resources

1 reference

12 December 2020

A cost-effectiveness clinical decision analysis model for schizophrenia

1 reference

12 December 2020

A comparison of clozapine and haloperidol in hospitalized patients with refractory schizophrenia. Department of Veterans Affairs Cooperative Study Group on Clozapine in Refractory Schizophrenia.

1 reference

12 December 2020

Reduction of hospital days in chronic schizophrenic patients treated with risperidone: a retrospective study

1 reference

12 December 2020

One hundred years of schizophrenia: a meta-analysis of the outcome literature.

1 reference

12 December 2020

Pharmacoeconomic evaluation of treatments for refractory schizophrenia: clozapine-related studies

1 reference

12 December 2020

Double-blind comparison of olanzapine versus risperidone in the treatment of schizophrenia and other psychotic disorders.

1 reference

12 December 2020

Use of risperidone and olanzapine in outpatient clinics at six Veterans Affairs hospitals

1 reference

12 December 2020

Cost-effectiveness of clozapine treatment in therapy-refractory schizophrenia.

1 reference

12 December 2020

Pharmacoeconomic studies of atypical antipsychotic drugs for the treatment of schizophrenia

1 reference

12 December 2020

Pharmacologic advances in the treatment of schizophrenia

1 reference

12 December 2020

A Canadian multicenter placebo-controlled study of fixed doses of risperidone and haloperidol in the treatment of chronic schizophrenic patients

1 reference

12 December 2020

[Cost effectiveness analysis of olanzapine versus haloperidol in the treatment of schizophrenia++ in Spain]

1 reference

12 December 2020

1 reference

12 December 2020

Olanzapine versus haloperidol in the treatment of schizophrenia and schizoaffective and schizophreniform disorders: results of an international collaborative trial

1 reference

12 December 2020

Drug utilization patterns and outcomes associated with in-hospital treatment with risperidone or olanzapine.

1 reference

12 December 2020

Evaluating outcomes of treatments for persons with psychotic disorders.

1 reference

12 December 2020

Assessment of costs and benefits of drug therapy for treatment-resistant schizophrenia in the United Kingdom.

1 reference

12 December 2020

Multiple fixed doses of "Seroquel" (quetiapine) in patients with acute exacerbation of schizophrenia: a comparison with haloperidol and placebo. The Seroquel Trial 13 Study Group

1 reference

12 December 2020

Estimating costs in the economic evaluation of medical technologies

1 reference

12 December 2020

Research Diagnoses for Tardive Dyskinesia

1 reference

12 December 2020

Tardive dyskinesia and atypical antipsychotic drugs

1 reference

12 December 2020

Olanzapine versus placebo and haloperidol: acute phase results of the North American double-blind olanzapine trial

1 reference

12 December 2020

Doses of olanzapine, risperidone, and haloperidol used in clinical practice: results of a prospective pharmacoepidemiologic study. EFESO Study Group. Estudio Farmacoepidemiologico en la Esquizofrenia con Olanzapina

1 reference

12 December 2020

Antipsychotic drugs and relapse prevention

1 reference

12 December 2020

Comments on "Double-Blind Comparison of Olanzapine Versus Risperidone in the Treatment of Schizophrenia and Other Psychotic Disorders" by Tran and Associates

1 reference

12 December 2020

A mental health capitation program: II. Cost-benefit analysis.

1 reference

12 December 2020

Anchoring the BPRS: an aid to improved reliability

1 reference

12 December 2020

A rating scale for extrapyramidal side effects

1 reference

12 December 2020

Methods of pharmacoeconomic evaluation of psychopharmacologic therapies for patients with schizophrenia

1 reference

12 December 2020

Neuropsychological change in early phase schizophrenia during 12 months of treatment with olanzapine, risperidone, or haloperidol. The Canadian Collaborative Group for research in schizophrenia

1 reference

12 December 2020

10.2165/00019053-200018060-00004

Identifiers

DOI

1 reference

19 April 2018

Dimensions Publication ID

1044592510

0 references

1 reference

19 April 2018